Patient information portal for congenital aortic and pulmonary valve disease: a stepped-wedge cluster randomised

Jonathan R G Etnel1, Lidia R Bons2, Frederiek De Heer3

  • 1Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands j.etnel@erasmusmc.nl.

Open Heart
|March 24, 2021
PubMed

Insights

An online patient information portal for congenital heart disease improved knowledge and mental health, but only for the 51.6% who accessed it. Effective implementation is key for these congenital heart disease (CHD) resources.

Area of Science:

  • Cardiology
  • Digital Health
  • Patient Education

Background:

  • Congenital heart disease (CHD) necessitates accessible patient information.
  • An online, evidence-based information portal was developed for patients with congenital aortic and pulmonary valve disease.
  • A stepped-wedge cluster randomised trial assessed the portal's effectiveness.

Purpose of the Study:

  • To evaluate the effectiveness of an online, evidence-based information portal for patients with congenital heart disease.
  • To assess the portal's impact on disease-specific knowledge, anxiety, depression, mental quality of life, and patient involvement.
  • To understand patient engagement with digital health resources in managing congenital heart disease.

Main Methods:

  • Adult patients and caregivers of paediatric patients with specific congenital heart conditions were prospectively included.
  • A stepped-wedge randomised design was used to introduce the information portal.
  • Participants completed questionnaires on various health and knowledge outcomes one month post-visit.

Main Results:

  • 343 participants were included; groups were comparable at baseline.
  • Intention-to-treat analyses showed no significant differences between groups.
  • However, among those who actually used the portal (51.6%), disease-specific knowledge and mental health were significantly improved.

Conclusions:

  • Only half of the invited participants accessed the online information portal.
  • Portal use was associated with significant improvements in disease knowledge and mental health.
  • Effective implementation strategies are crucial for maximizing the benefits of online patient information portals in clinical practice for congenital heart disease.
Abstract

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
127
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
142
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
95
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
315
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K